Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Publikation

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Wissenschaftlicher Artikel/Review - 13.01.2023

Núñez Nicolás Gonzalo, Berner Fiamma, Friebel Ekaterina, Unger Susanne, Wyss Nina, Gomez Julia Martinez, Purde Mette-Triin, Niederer Rebekka, Porsch Maximilian, Lichtensteiger Christa, Kramer Rafaela, Erdmann Michael, Schmitt Christina, Heinzerling Lucie, Abdou Marie-Therese, Karbach Julia, Schadendorf Dirk, Zimmer Lisa, Ugurel Selma, Klümper Niklas, Hölzel Michael, Power Laura, Kreutmair Stefanie, Capone Mariaelena, Madonna Gabriele, Cevhertas Lacin, Heider Anja, Amaral Teresa, Hasan Ali Omar, Bomze David, Dimitriou Florentia, Diem Stefan, Ascierto Paolo Antonio, Dummer Reinhard, Jäger Elke, Driessen Christoph, Levesque Mitchell Paul, van de Veen Willem, Joerger Markus, Früh Martin, Becher Burkhard, Flatz Lukas

Zitation

Núñez N, Berner F, Friebel E, Unger S, Wyss N, Gomez J, Purde M, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou M, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto P, Dummer R, Jäger E, Driessen C, Levesque M, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y) 2023

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Med (N Y) 2023

Veröffentlichungsdatum

13.01.2023

eISSN (Online)

2666-6340

Kurzbeschreibung/Zielsetzung

Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce effective anti-tumor responses, they may also drive serious immune-related adverse events (irAEs). Identifying biomarkers to predict which patients will suffer from irAEs would enable more accurate clinical risk-benefit analysis for ICI treatment and may also shed light on common or distinct mechanisms underpinning treatment success and irAEs.